An agreement has been finalized for QIAGEN to fully acquire Parse Biosciencesa leading provider of scalable, instrument-free solutions for single-cell research. This strategic move is expected to significantly strengthen QIAGEN’s presence in the rapidly growing single-cell sequencing market.

Parse is a fast-growing innovator in single-cell sample preparation, whose proprietary Evercode platform enables instrument-free, high-throughput RNA workflows for analyzing millions and billions of cells, a capability that distinguishes it from other single-cell offerings and is vital for large-scale AI-driven biology.

The global single-cell market is projected to nearly double, expanding from an estimated $1.2 billion in 2024 to $2.1 billion by 2029, a growth trajectory driven by the increasing need for massive cellular datasets to fuel AI-based drug discovery and model health and disease at a mechanistic level. By integrating Parse's technology and its GigaLab high-throughput service into its industry-leading Sample technologies portfolio and its QIAGEN Digital Insights (QDI) bioinformatics offering, QIAGEN aims to provide researchers with end-to-end tools to efficiently generate, process, and interpret these large datasets.

Parse's products are already widely adopted, utilized by over 3,000 labs globally, including all of the top 50 research institutions. The transaction, which is subject to customary closing conditions, is expected to be completed in December 2025, with QIAGEN paying an upfront sum of approximately $225 million in cash, along with potential additional milestone payments of up to $55 million. Parse is projected to contribute about $40 million in sales to QIAGEN in 2026, with sales expected to increase at a strong double-digit rate in subsequent years.